未登录

W

William Cruz-Muñoz

sunnybrook research institute

H指数:19

被引数:3,113

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Modulation of fibronectin extracellular matrix enhances anti-tumor efficacy of immune checkpoint blockade

调节纤维连接蛋白细胞外基质可增强免疫检查点抑制剂的抗肿瘤疗效

Cell Reports Medicine

IF10.6

2025-09-080

OAAI

Targeted Nanoparticle for Co-delivery of HER2 siRNA and a Taxane to Mirror the Standard Treatment of HER2+Breast Cancer: Efficacy in Breast Tumor and Brain Metastasis

IF12.1

2022-01-2730

OA

Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer

EMBO MOLECULAR MEDICINE

IF8.3

2021-06-1425

OAAI

Metronomic chemotherapy offsets HIFα induction upon maximum-tolerated dose in metastatic cancers

EMBO MOLECULAR MEDICINE

IF8.3

2020-07-2022

OAAI

Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer

NPJ BREAST CANCER

IF7.6

2020-07-2023

OAAI

PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis

CLINICAL CANCER RESEARCH

IF10.2

2015-04-3066

OAAI

Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy

EMBO MOLECULAR MEDICINE

IF8.3

2014-10-3142

OAAI

Derivation and analysis of preclinical models of human her-2 positive breast cancer

CANCER RESEARCH

IF16.6

2014-10-011

PRE

Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer

IF9.2

2014-02-2621

OA

Development and characterization of a clinically relevant mouse model of melanoma brain metastasis

PIGMENT CELL & MELANOMA RESEARCH

IF2.6

2013-06-0423

OAAI

Roles for Endothelin Receptor B and BCL2A1 in Spontaneous CNS Metastasis of Melanoma

CANCER RESEARCH

IF16.6

2012-09-3058

OAAI

Contrasting effects of VEGF pathway inhibitors in primary and metastatic disease using perioperative neoadjuvant mouse models

CANCER RESEARCH

IF16.6

2012-04-010

PRE

Preclinical approaches to study the biology and treatment of brain metastases

SEMINARS IN CANCER BIOLOGY

IF15.7

2011-04-0144

OAAI

Mouse models of advanced spontaneous metastasis for experimental therapeutics

NATURE REVIEWS CANCER

IF66.8

2011-01-24329

OAAI

Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer

MOLECULAR CANCER THERAPEUTICS

IF5.5

2010-04-0796

OAAI

Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer

MOLECULAR CANCER THERAPEUTICS

IF5.5

2009-12-010

PRE

Effective Treatment of Advanced Human Melanoma Metastasis in Immunodeficient Mice Using Combination Metronomic Chemotherapy Regimens

CLINICAL CANCER RESEARCH

IF10.2

2009-07-2931

OAAI

Comment re: Preclinical Model of Spontaneous Melanoma Metastasis Response

CANCER RESEARCH

IF16.6

2009-01-150

PREAI

The role of tissue inhibitors of metalloproteinases in tumorigenesis and metastasis

CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES

IF5.5

2008-10-10108

PREAI

Development of a preclinical model of spontaneous human melanoma central nervous system metastasis

CANCER RESEARCH

IF16.6

2008-06-16120

OAAI